Patents by Inventor Danila Valmori

Danila Valmori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NY-ESO-1-peptide derivatives, and uses thereof
    Patent number: 6417165
    Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerrotini, Pedro Romero
  • Isolated decapeptides which bind to HLA molecules
    Patent number: 6384190
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Method for provoking proliferation of cytolytic T cells via the use of decapeptides which complex with HLA-A2 molecules
    Patent number: 6368857
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: April 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof
    Patent number: 6326200
    Abstract: Cytolytic T cells specific to complexes J HLA-A2 molecules and peptides are described as are methods for provoking the cytolytic T cells. The peptides of SEQ ID NOS: 13, 14 and 15 are preferred peptides.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: December 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
    Patent number: 6277956
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: August 21, 2001
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
    Patent number: 6025470
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: February 15, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero